2415 (2415) Fair Value & Analysis

Healthcare · Market cap HK$526M

2 2415 2415 · HK

PriceHK$0.9600

Fair ValueHK$0.8300

Upside-13.5%

Quality40/100

Watch 2415 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.6200 – HK$1.04

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −2.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.8800 – HK$2.26 · fair‑value band HK$0.6200 – HK$1.04 · the HK$0.9600 price screens above the HK$0.8300 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2415 (2415) currently trades at HK$0.9600, while our model-based Fair Value estimate is HK$0.8300 — implying the stock looks roughly 13.5% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2415 generated revenue of HK$270M at a net margin of 6.6%. Revenue declined 3.2% year over year. It earns a return on equity of 1.5%. The stock trades on a trailing P/E of 32.0. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$270M

Revenue growth (YoY) -3.2%

Net margin 6.6%

Return on equity 1.5%

Free cash flow HK$2.0M FY2025

P/E ratio 32.0

More key figures

Operating margin 13.5%

EPS (TTM) HK$0.0200

Dividend yield 1.0%

EPS growth (YoY) -87.5%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2415 reported revenue of HK$270M in FY2025 versus HK$298M in FY2021, a compound −2.4%/yr. Reported net income was HK$17.9M in FY2025.

Revenue −2.4%/yr

FY21 HK$298M

FY22 HK$349M

FY23 HK$349M

FY24 HK$261M

FY25 HK$270M

Net income

FY21 −HK$151M

FY22 −HK$99.9M

FY23 HK$55.0M

FY24 HK$25.0M

FY25 HK$17.9M

Is 2415 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$66.84	$21.63	-68%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2415 (2415) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8300 versus a price of HK$0.9600 — about −14% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2415?

Our model-based fair value for 2415 is HK$0.8300 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.9600.

What is the quality score of 2415?

2415 has a Quality Score of 40/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2415 (2415)?

2415 reported trailing-twelve-month revenue of about HK$270M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2415?

The net profit margin of 2415 is about 6.6%, meaning it keeps roughly 6.6% of revenue as net income. Based on the latest reported figures.

Does 2415 pay a dividend?

2415 currently shows a dividend yield of about 1.03% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.